Individualized antithrombotic therapy and selective use of CEPDs are essential for stroke prevention in patients undergoing TAVR, despite uncertain benefits from trials.
Do cerebral embolic protection devices reduce stroke in patients undergoing transcatheter aortic valve replacement?
Current evidence does not support the routine use of cerebral embolic protection devices during TAVR to prevent stroke, suggesting a need for selective application and individualized antithrombotic therapy.
Absolute Event Rate: 0% vs 0%
While some studies suggest CEPDs may reduce stroke, randomized trials have not confirmed broad and robust benefit, and high cost limits routine adoption. Future work should focus on high-risk subgroups, device refinement, and large-scale trials. For now, individualized antithrombotic therapy and selective CEPD use remain central to stroke prevention in TAVR.
Hajj et al. (Thu,) reported a other. Individualized antithrombotic therapy and selective use of CEPDs are essential for stroke prevention in patients undergoing TAVR, despite uncertain benefits from trials.